Welcome to our dedicated page for Meiragtx Holdings Plc SEC filings (Ticker: MGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MeiraGTx Holdings plc (Nasdaq: MGTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage genetic medicines company with programs in ophthalmology, Parkinson’s disease and radiation-induced xerostomia, MeiraGTx uses SEC reports to communicate material events, financial results and key collaboration agreements to investors.
Among the filings available are current reports on Form 8-K, which MeiraGTx has used to announce quarterly financial and operational results, strategic collaborations and regulatory milestones. For example, the company has filed 8-Ks describing its strategic collaboration and license agreement with Eli Lilly and Company in ophthalmology, its broad collaboration with Hologen Limited to form Hologen Neuro AI Ltd, and the receipt of foreign direct investment clearances related to that collaboration. Other 8-Ks reference the release of financial results for specific quarters.
In addition to current reports, investors can use this page to locate MeiraGTx’s periodic filings, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, when available. These documents typically contain detailed discussions of the company’s clinical pipeline, including programs like AAV-AIPL1, AAV2-hAQP1 and AAV-GAD, as well as risk factors, management’s discussion and analysis, and information on its manufacturing infrastructure and collaborations.
Stock Titan enhances access to these filings by providing real-time updates from the SEC’s EDGAR system and AI-powered summaries that explain the key points in plain language. Users can quickly see which filings relate to clinical data, regulatory designations, strategic partnerships or financing. The filings page also surfaces information on items such as material definitive agreements, like the collaboration and license agreement with Eli Lilly, and other disclosures that may affect MeiraGTx’s development plans and capital position.
For those tracking MeiraGTx’s progress in genetic medicine, this page offers a structured view of how the company reports its activities to regulators and the market, from clinical and regulatory milestones to manufacturing and partnership developments.
MeiraGTx Holdings plc CFO & COO Richard Giroux reported an open-market sale of 56,000 Ordinary Shares at a weighted average price of $10.22 per share. The sale was executed as a single economic event across multiple trades at prices ranging from $9.96 to $10.60.
Following this transaction, Giroux directly holds 971,530 Ordinary Shares. He also reports indirect ownership of 85,000 shares through Aigle Healthcare Partners III LLC and 5,152 shares held by his spouse. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025.
MeiraGTx Holdings plc is offering 11,111,111 ordinary shares at an offering price of $9.00 per share, for gross proceeds of $99,999,999. After underwriting discounts and commissions, proceeds to the company before expenses are shown as $93,999,999, with estimated net proceeds of approximately $93.3 million.
The prospectus supplement states ordinary shares outstanding were 81,446,126 as of March 31, 2026 and would be 92,557,237 immediately after this offering. The company plans to use net proceeds for general corporate purposes, including working capital and capital expenditures. The offering is underwritten by BofA Securities, Goldman Sachs and Raymond James.
MeiraGTx Holdings plc is offering 11,111,111 ordinary shares at an offering price of $9.00 per share, for gross proceeds of $99,999,999. After underwriting discounts and commissions, proceeds to the company before expenses are shown as $93,999,999, with estimated net proceeds of approximately $93.3 million.
The prospectus supplement states ordinary shares outstanding were 81,446,126 as of March 31, 2026 and would be 92,557,237 immediately after this offering. The company plans to use net proceeds for general corporate purposes, including working capital and capital expenditures. The offering is underwritten by BofA Securities, Goldman Sachs and Raymond James.
MeiraGTx Holdings plc is offering 11,111,111 ordinary shares at an offering price of $9.00 per share, for gross proceeds of $99,999,999. After underwriting discounts and commissions, proceeds to the company before expenses are shown as $93,999,999, with estimated net proceeds of approximately $93.3 million.
The prospectus supplement states ordinary shares outstanding were 81,446,126 as of March 31, 2026 and would be 92,557,237 immediately after this offering. The company plans to use net proceeds for general corporate purposes, including working capital and capital expenditures. The offering is underwritten by BofA Securities, Goldman Sachs and Raymond James.
MeiraGTx Holdings plc entered an underwriting agreement for a public offering of 11,111,111 ordinary shares at $9.00 per share under its effective shelf registration. All shares are being sold by the company.
The company expects net proceeds of about $93.3 million, to be used for general corporate purposes, including working capital and capital expenditures. Management states that, together with existing cash and cash equivalents, this funding should cover operating and capital needs, including potential commercial launches of bota-vec for X‑linked retinitis pigmentosa and AAV‑hAQP1 for radiation-induced xerostomia, in each case if approved, into the second half of 2028.
MeiraGTx Holdings plc entered an underwriting agreement for a public offering of 11,111,111 ordinary shares at $9.00 per share under its effective shelf registration. All shares are being sold by the company.
The company expects net proceeds of about $93.3 million, to be used for general corporate purposes, including working capital and capital expenditures. Management states that, together with existing cash and cash equivalents, this funding should cover operating and capital needs, including potential commercial launches of bota-vec for X‑linked retinitis pigmentosa and AAV‑hAQP1 for radiation-induced xerostomia, in each case if approved, into the second half of 2028.
MeiraGTx Holdings plc entered an underwriting agreement for a public offering of 11,111,111 ordinary shares at $9.00 per share under its effective shelf registration. All shares are being sold by the company.
The company expects net proceeds of about $93.3 million, to be used for general corporate purposes, including working capital and capital expenditures. Management states that, together with existing cash and cash equivalents, this funding should cover operating and capital needs, including potential commercial launches of bota-vec for X‑linked retinitis pigmentosa and AAV‑hAQP1 for radiation-induced xerostomia, in each case if approved, into the second half of 2028.
MeiraGTx Holdings plc has reacquired full rights to botaretigene sparoparvovec (bota-vec), its gene therapy for X-linked retinitis pigmentosa (XLRP), through an asset purchase from Janssen Pharmaceuticals. The company will pay an upfront $25 million in cash, a $50 million contingent milestone tied to U.S. approval and U.S. net sales first exceeding $250 million, and mid-teens royalties on global net sales commencing on or after July 1, 2029.
The deal transfers Janssen’s UCL license and related RPGR program assets and includes a perpetual, worldwide license to key know-how and patents. Johnson & Johnson’s investment arm, a holder of more than 5% of MeiraGTx shares, agreed to a 12-month lockup on its holdings plus advance notice before any later sales. MeiraGTx plans rapid U.S., EU and Japan filings for bota-vec, aiming for a potential launch in 2027, and ultimately expects to become a commercial-stage company with two products, including AAV-hAQP1 for radiation-induced xerostomia, over the next two years.
MeiraGTx Holdings plc has reacquired full rights to botaretigene sparoparvovec (bota-vec), its gene therapy for X-linked retinitis pigmentosa (XLRP), through an asset purchase from Janssen Pharmaceuticals. The company will pay an upfront $25 million in cash, a $50 million contingent milestone tied to U.S. approval and U.S. net sales first exceeding $250 million, and mid-teens royalties on global net sales commencing on or after July 1, 2029.
The deal transfers Janssen’s UCL license and related RPGR program assets and includes a perpetual, worldwide license to key know-how and patents. Johnson & Johnson’s investment arm, a holder of more than 5% of MeiraGTx shares, agreed to a 12-month lockup on its holdings plus advance notice before any later sales. MeiraGTx plans rapid U.S., EU and Japan filings for bota-vec, aiming for a potential launch in 2027, and ultimately expects to become a commercial-stage company with two products, including AAV-hAQP1 for radiation-induced xerostomia, over the next two years.
MeiraGTx Holdings plc has reacquired full rights to botaretigene sparoparvovec (bota-vec), its gene therapy for X-linked retinitis pigmentosa (XLRP), through an asset purchase from Janssen Pharmaceuticals. The company will pay an upfront $25 million in cash, a $50 million contingent milestone tied to U.S. approval and U.S. net sales first exceeding $250 million, and mid-teens royalties on global net sales commencing on or after July 1, 2029.
The deal transfers Janssen’s UCL license and related RPGR program assets and includes a perpetual, worldwide license to key know-how and patents. Johnson & Johnson’s investment arm, a holder of more than 5% of MeiraGTx shares, agreed to a 12-month lockup on its holdings plus advance notice before any later sales. MeiraGTx plans rapid U.S., EU and Japan filings for bota-vec, aiming for a potential launch in 2027, and ultimately expects to become a commercial-stage company with two products, including AAV-hAQP1 for radiation-induced xerostomia, over the next two years.
MeiraGTx Holdings plc reports positive three-year follow-up data from its Phase 1 AQUAx study of AAV‑hAQP1, a one-time gene therapy for grade 2/3 late radiation‑induced xerostomia. The treatment was observed to be safe and well tolerated across doses, with no dose‑limiting toxicity or treatment‑related serious adverse events.
Clinically meaningful symptom improvements on the Xerostomia Questionnaire and increases in Unstimulated Whole Saliva Flow Rate were maintained out to 36 months, suggesting durable benefit. The company highlights RIX as a severe, lifelong condition with no effective treatments, affecting an estimated 165,000 patients in the U.S. and about 435,000 globally.
Market research cited by MeiraGTx shows strong physician enthusiasm, with approximately 78% clinician‑stated preference translating to around 52% projected usage after adjustment and roughly 90% estimated U.S. market access coverage. Based on commissioned research, the company estimates peak global annual revenue potential of about $3.7 billion, with a steady‑state of $3.2 billion globally and $2.0 billion peak and $1.8 billion steady‑state in the U.S. in the late 2030s, though these figures are forward‑looking and subject to significant development and regulatory risks outlined in its risk disclosures.
MeiraGTx Holdings plc reports positive three-year follow-up data from its Phase 1 AQUAx study of AAV‑hAQP1, a one-time gene therapy for grade 2/3 late radiation‑induced xerostomia. The treatment was observed to be safe and well tolerated across doses, with no dose‑limiting toxicity or treatment‑related serious adverse events.
Clinically meaningful symptom improvements on the Xerostomia Questionnaire and increases in Unstimulated Whole Saliva Flow Rate were maintained out to 36 months, suggesting durable benefit. The company highlights RIX as a severe, lifelong condition with no effective treatments, affecting an estimated 165,000 patients in the U.S. and about 435,000 globally.
Market research cited by MeiraGTx shows strong physician enthusiasm, with approximately 78% clinician‑stated preference translating to around 52% projected usage after adjustment and roughly 90% estimated U.S. market access coverage. Based on commissioned research, the company estimates peak global annual revenue potential of about $3.7 billion, with a steady‑state of $3.2 billion globally and $2.0 billion peak and $1.8 billion steady‑state in the U.S. in the late 2030s, though these figures are forward‑looking and subject to significant development and regulatory risks outlined in its risk disclosures.
MeiraGTx Holdings plc reports positive three-year follow-up data from its Phase 1 AQUAx study of AAV‑hAQP1, a one-time gene therapy for grade 2/3 late radiation‑induced xerostomia. The treatment was observed to be safe and well tolerated across doses, with no dose‑limiting toxicity or treatment‑related serious adverse events.
Clinically meaningful symptom improvements on the Xerostomia Questionnaire and increases in Unstimulated Whole Saliva Flow Rate were maintained out to 36 months, suggesting durable benefit. The company highlights RIX as a severe, lifelong condition with no effective treatments, affecting an estimated 165,000 patients in the U.S. and about 435,000 globally.
Market research cited by MeiraGTx shows strong physician enthusiasm, with approximately 78% clinician‑stated preference translating to around 52% projected usage after adjustment and roughly 90% estimated U.S. market access coverage. Based on commissioned research, the company estimates peak global annual revenue potential of about $3.7 billion, with a steady‑state of $3.2 billion globally and $2.0 billion peak and $1.8 billion steady‑state in the U.S. in the late 2030s, though these figures are forward‑looking and subject to significant development and regulatory risks outlined in its risk disclosures.
MeiraGTx Holdings plc chief development officer Stuart Naylor reported an open-market sale of 27,661 Ordinary Shares of MGTX on April 7, 2026. The shares were sold at a weighted average price of $9.36, in multiple trades between $9.11 and $9.52 per share.
After this transaction, Naylor directly holds 668,505 Ordinary Shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025, indicating it was planned in advance rather than timed discretionarily.
MeiraGTx Holdings plc outlines its business as a vertically integrated, clinical-stage genetic medicines company focused on xerostomia, neurodegenerative disease and inherited retinal disorders. It highlights late-stage programs such as AAV‑hAQP1 for radiation‑induced xerostomia and AAV‑GAD for Parkinson’s disease, both supported by favorable early clinical data and U.S. FDA regenerative medicine designations.
The company emphasizes ownership of two GMP viral vector and plasmid manufacturing campuses in London and Shannon, designed to support clinical through commercial supply. MeiraGTx also describes a proprietary riboswitch gene regulation platform for orally controlled expression of biologics and cell therapies, and multiple strategic collaborations with Johnson & Johnson, Hologen and Eli Lilly that bring upfront payments, development funding and significant potential milestones.
MeiraGTx Holdings plc amended its credit facility with Perceptive, extending the notes’ maturity from August 2, 2026 to May 2, 2027 and committing to redeem $25.0 million of principal on or before June 30, 2026. Related warrants for 700,000 ordinary shares were repriced to $8.00 per share. The company reported 2025 revenue of $81.4 million, driven by a $75.0 million upfront license payment from Eli Lilly, and a net loss of $114.2 million versus $147.8 million in 2024. Cash and cash equivalents were $65.9 million as of December 31, 2025. Management believes existing cash, receivables and collaboration funding can support operations into the second half of 2027 and cover scheduled debt repayments of $25.0 million due June 2026 and $50.0 million due May 2027. The FDA granted Breakthrough Therapy Designation to AAV2-hAQP1 for Grade 2/3 radiation-induced xerostomia, and the company highlighted strategic collaborations with Eli Lilly and Hologen and progress in its riboswitch gene regulation platform.